Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Denali Therapeutics Inc shares valued at $284,097 were purchased by Ho Carole on Jan 06 ’26. At $16.50 per share, Ho Carole acquired 17,218 shares.
Also, Schuth Alexander O. purchased 17,218 shares, netting a total of over 284,097 in proceeds.
Before that, Watts Ryan J. had added 35,198 shares to its account. In a trade valued at $580,767, the Director bought Denali Therapeutics Inc shares for $16.50 each.
Analysts at Cantor Fitzgerald upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in early April. Earlier on February 11, 2025, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for DNLI stock.
Analyzing DNLI Stock Performance
On last trading session, Denali Therapeutics Inc [NASDAQ: DNLI] plunged -1.51% to $16.95. The stock’s lowest price that day was $16.7, but it reached a high of $17.95 in the same session. During the last five days, there has been a surge of approximately 3.29%. Over the course of the year, Denali Therapeutics Inc shares have dropped approximately -20.27%. Shares of the company reached a 52-week high of $17.95 on 01/07/26 and a 52-week low of $15.34 on 01/05/26.
Support And Resistance Levels for Denali Therapeutics Inc (DNLI)
According to the 24-hour chart, there is a support level at 16.45, which, if violated, would cause prices to drop to 15.95. In the upper region, resistance lies at 17.70. The next price resistance is at 18.45. RSI (Relative Strength Index) is 48.45 on the 14-day chart, showing neutral technical sentiment.
Is Denali Therapeutics Inc subject to short interest?
Stocks of Denali Therapeutics Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.92 million shares to 13.09 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 14.02 million shares. A decline of -7.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.35 of the overall float, the days-to-cover ratio (short ratio) decline to 7.35.
Which companies own the most shares of Denali Therapeutics Inc (DNLI)?
In terms of Denali Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 74.32% from the previous closing price of $17.21. Analysts anticipate Denali Therapeutics Inc stock to reach 37 by 2026, with the lowest price target being 25. In spite of this, 4 analysts ranked Denali Therapeutics Inc stock as Buy at the end of 2026. On January 07, 2025, Robert W. Baird assigned a price target of “an Outperform” to the stock and initiated coverage with a $31.
